Coronavirus (COVID-19) Pandemic: Concern about Misuse of Antibiotics
Keywords:Coronavirus; COVID-19; Outbreak; Developing countries; Antibiotics
Novel coronavirus, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, which has been a global threat for human health. The infection of coronavirus spread worldwide. Particularly, the rapid spread in the South American and Asian countries is concerning where population density is very high, and health facilities are inadequate compared to developed countries. In developing countries, people are less willing to go to physicians or hospitals to diagnose diseases. Self-medication is a widespread and prominent practice in those countries, particularly taking of antibiotics. Hence, antibiotics, particularly azithromycin and other last-resort antibiotics related to respiratory tract infection, might be misused or overused for COVID-19 treatment. Therefore, we recommend to the responsible authorities to take an urgent initiative to concern the people of developing and least developed countries about the misuse or overuse of antibiotics against the coronavirus.
Biswas M, Roy MN, Manik MIN, Hossain MS, Tapu STA, Moniruzzaman M, Sultana S (2014). “Self medicated antibiotics in Bangladesh: a cross-sectional health survey conducted in the Rajshahi City.” BMC public health, 14(1), 847. doi:10.1186/1471-2458-14-847.
FDA (2020). “Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment. Accessed May, 2020.” URL https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-updatefda-issues-emergency-use-authorization-potential-covid-19-treatment.
Gao J, Tian Z, Yang X (2020). “Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.” Bioscience trends. doi:10.5582/bst.2020.01047.
Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, et al. (2020). “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.” International journal of antimicrobial agents, p. 105949. doi:10.1016/j.ijantimicag.2020.105949.
Glasgow Times (2020). “Potential coronavirus treatment to be trialled in Scotland. Accessed May, 2020.” URL https://www.glasgowtimes.co.uk/news/18350585.potentialcoronavirus-treatment-trialled-scotland/.
Hoque R, Ahmed SM, Naher N, Islam MA, Rousham EK, Islam BZ, Hassan S (2020). “Tackling antimicrobial resistance in Bangladesh: A scoping review of policy and practice in human, animal and environment sectors.” PloS One, 15(1), e0227947. doi:10.1371/journal.pone.0227947.
Hossain MS, Ferdous S, Siddiqee MH (2020). “Mass panic during Covid-19 outbreak-A perspective from Bangladesh as a high-risk country.” Journal of Biomedical Analytics, 3(2), 1–3. doi:10.30577/jba.v3i2.40.
Li C, Zu S, Deng YQ, Li D, Parvatiyar K, Quanquin N, Shang J, Sun N, Su J, Liu Z, et al. (2019). “Azithromycin protects against Zika virus infection by upregulating virus-induced type I and III interferon responses.” Antimicrobial Agents and Chemotherapy, 63(12). doi:10.1128/AAC.00394-19.
NIH (2020). “NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19. Accessed May, 2020.” URL https://www.nih.gov/news-events/newsreleases/nih-begins-clinical-trial-hydroxychloroquine-azithromycin-treat-covid-19.
Safain KS, Bhuyan GS, Tasnim S, Hasib SH, Sultana R, Islam MS, Al Mahmud-Un-Nabi M, Sarker SK, Noor FA, Rahat A, et al. (2020). “Situation of antibiotic resistance in Bangladesh and its association with resistance genes for horizontal transfer.” bioRxiv. doi:10.1101/2020.04.06.027391.
The Business Standard (2020). “Bangladesh recommends controversial drugs for Covid-19 treatment. Accessed May, 2020.” URL https://tbsnews.net/coronavirus-chronicle/covid-19-bangladesh/bangladesh-recommends-controversial-drugs-covid-19.
The Japan Times (2020). “Japan health ministry expediting remdesivir for COVID-19 patients. Accessed May, 2020.” URL
The New York Times (2020). “Doctors Heavily Overprescribed Antibiotics Early in the Pandemic. Accessed June, 2020.” URL
UN (2019). “No Time to Wait: Securing the future from drug-resistant infections.” URL https://www.who.int/antimicrobial-resistance/interagency-coordinationgroup/final-report/en/.
van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A,Williamson BN, Tamin A, Harcourt JL, Thornburg NJ, Gerber SI, et al. (2020). “Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1.” New England Journal of Medicine, 382(16), 1564–1567. doi:10.1056/NEJMc2004973.
WHO (2020). “Coronavirus disease (COVID-2019) situation reports. Geneva: World Health Organization. Accessed April, 2020.” URL https://www.WHO.Int/docs/defaultsource/coronaviruse/situationreports/20200221-sitrep-32-covid.
Worldometers (2020). “COVID-19 coronavirus outbreak live update. Accessed May 08, 2020.” URL https://www.worldometers.info/coronavirus/.
Xu J, Zhao S, Teng T, Abdalla AE, Zhu W, Xie L, Wang Y, Guo X (2020). “Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARSCoV.” Viruses, 12(2), 244. doi:10.3390/v12020244.
Zeenews (2020). “COVID-19 cure in sight? Bangladeshi doctors claim Ivermectin with Doxycycline can treat coronavirus patients. Accessed June, 2020.” URL https://zeenews.india.com/india/covid-19-cure-in-sight-bangladeshi-doctors-claimivermectin-with-doxycycline-can-treat-coronavirus-patients-2285317.html.
How to Cite
Copyright (c) 2020 Anwar Hossain, Md. Raknuzzaman, Masahiro Tokumura
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Submission of any work for publication in this journal would imply that the authors acknowledge that the work is their own and that they have taken all necessary permissions for all the materials used in their work.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors permit us for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.